Immupharma PLC IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASET 2020
December 03 2019 - 2:01AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
03 December 2019
RNS REACH 3 December 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASE(TM) 2020 IN SAN
FRANCISCO
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and
development company, is pleased to announced that it will be
presenting at the Biotech Showcase(TM) 2020, to be held between
13-15 January 2020, at the Hilton, San Francisco Union Square.
Dr Tim Franklin, Commercial Advisor to ImmuPharma, will be
presenting to conference attendees on 14th January 2020 at 10:30am
(EST) in room Yosemite C (Ballroom Level). If you are attending the
event and would like to meet with Dr Franklin for a one to one
meeting, please contact Lisa Baderoon, Head of Investor Relations,
who will be able to arrange a meeting:
lisa.baderoon@immupharma.com.
Commenting on the event, Dimitri Dimitrou, CEO of ImmuPharma
said: "Following on from our recent licensing and development
agreement with Avion, the US speciality pharmaceutical company, in
which Avion will fund an international Phase III trial for our lead
programme, Lupuzor(TM), the investment thesis for ImmuPharma and
specifically Lupuzor(TM) has been repositioned. We are delighted
that Dr Franklin, who was an integral part of the ImmuPharma team
involved in the Avion negotiations, will be representing ImmuPharma
and presenting at this prestigious Biotech Showcase. This will be a
great opportunity to refocus the industry's and investors' minds on
the significant potential within ImmuPharma's pipeline."
Biotech Showcase, produced by Demy-Colton and EBD Group, is an
investor conference focused on driving advances in therapeutic
development by providing a sophisticated networking platform for
executives and investors that fosters investment and partnership
opportunities. The conference takes place each year during the
course of one of the industry's largest gatherings and busiest
weeks.
"We are delighted that ImmuPharma will be presenting at Biotech
Showcase this year," said Sara Demy, CEO of Demy-Colton. "Biotech
Showcase is a prime occasion for life science entrepreneurs and
investors to come together to discover the potential of innovative
technologies that will drive the future of drug discovery."
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 8974
Vassil Kirtchev
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
company portfolio includes novel peptide therapeutics for
autoimmune diseases, metabolic diseases and cancer. The lead
program, Lupuzor(TM) , is a first-in class autophagy
immunomodulator which is in Phase III for the treatment of lupus
and preclinical analysis suggest therapeutic activity for many
other autoimmune diseases that share the same autophagy mechanism
of action. For additional information about ImmuPharma please visit
www.immupharma.com.
About Biotech Showcase
Biotech Showcase is an investor and networking conference
devoted to providing private and public biotechnology and life
sciences companies with an opportunity to present to, and meet
with, investors and pharmaceutical executives in one place.
Investors and biopharmaceutical executives from around the world
gather in San Francisco during this bellwether week which sets the
tone for the coming year. Now in its 12th year, this
well-established, highly respected conference features multiple
tracks of presenting companies, plenary sessions, workshops,
networking, and an opportunity to schedule one-to-one meetings.
Biotech Showcase is produced by Demy-Colton and EBD Group. Both
organizations have a long history of producing high-quality
programs that support the biotechnology and broader life sciences
industry.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases such as
marketing messages, corporate and product information into the
public domain. An RNS Regulatory announcement is required to be
notified under the AIM Rules for Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUUSNRKKAURAA
(END) Dow Jones Newswires
December 03, 2019 02:01 ET (07:01 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024